Using other clinical test results in Step 2, such as for a previously reported polygenic risk score5, or the degree of depression, or the presence of anxiety or RBD, or the result of a reduction in select CSF biomarker levels (such as for total α-synuclein or total tau), a small AUC increase was observed in many -but not all- cases (Supplementary Figure 1). This evidence concerns the gene MAPT and depressive symptom measurement.